Dr Laura Price is a consultant respiratory physician at Royal Brompton and Harefield hospitals.
Dr Price attained an intercalated BSc in cellular and molecular pathology in 1995 and then went on to graduate in medicine from the University of Bristol in 1998. She has comprehensive training in general, respiratory and critical care medicine. During her training posts, she gained experience in anaesthesia from the Fellowship of the Royal College of Anaesthetists (FRCA).
Dr Price undertook specialist training on the North West London rotation between 2005 and 2013 and in this time gained a PhD in pulmonary hypertension from Imperial College London. To advance her clinical and research experience in this condition she spent 12 months in the largest pulmonary hypertension centre in Paris, France.
Dr Laura Price is a clinical expert in lung disease, chronic obstructive pulmonary disease (COPD), sleep disorders, pulmonary fibrosis and interstitial lung disease. Royal Brompton and Harefield hospitals run a National Pulmonary Hypertension Service where Dr Price is a valued member of the team who consults patients with pulmonary hypertension and other pulmonary vascular diseases.
Dr Price leads our outpatient pulmonary hypertension clinics and is the lead consultant for inpatients diagnosed with this condition and all emergencies relating to pulmonary hypertension. She is in the process of establishing a new service following up patients after pulmonary emboli, with her haematology colleagues at the Royal Brompton Hospital.
Dr Laura Price continues to research chronic obstructive pulmonary disease (COPD), sleep disorders and pulmonary hypertension in lung diseases, notably interstitial lung disease. She continues her research project as a co-applicant to study the benefits of specific drugs in patients with COPD for the National Institute for Health Research (NIHR).
Dr Price’s PhD research indicated that patients with idiopathic pulmonary arterial hypertension, the key inflammatory signalling molecule NF-kappa B, was enhanced in patients’ lungs for this group. Using corticosteroids in a disease model and in relevant lung cells showed that suppression of inflammation in pulmonary arterial hypertension might be a potential therapeutic marker.
Dr Laura Price has authored numerous book chapters, her PhD led to four well-cited peer-reviewed publications and she has written on a wide range of topics in respiratory disease and many articles on pulmonary hypertension and critical care.
Dr Laura Price uses her clinical expertise in training undergraduate and postgraduates. She is also an honorary clinical senior lecturer at the National Heart and Lung Institute at Imperial College London.